Human Placental-Derived Stem Cell Transplantation (HPDSC) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01586455

Human Placental-Derived Stem Cell Transplantation (HPDSC)
For more details on this clinical trial, including contact information, please see this trial’s listing on

The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.

Study Date: 
Mon, 04/01/2013 to Sat, 12/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Drug: Human Placental Derived Stem Cell Infusions of thawed HPDSC to be given following UCB infusion. Other Name: HPDSC